The parts that carry over are the parts operators think about: the chair, the room, the comfort with needles, the patients who already trust you. The parts that do not carry over are the ones that decide whether this works.
Two things change the regulatory shape of the business. Testosterone is a controlled substance, and hormone programs run on laboratory values. Each pulls in a regime an IV clinic has probably never touched.
The controlled substance layer
Adding testosterone means the clinic now handles a scheduled drug, and the registration question attaches to your address. Under 21 CFR § 1301.12(a) a separate registration is required for each principal place of business or professional practice at one general physical location where controlled substances are dispensed. Our treatment is at DEA registration by location.
That brings with it, in rough order of how often it is missed:
- Registration for each site, if you operate more than one.
- State controlled-substance registration, which is separate in many states.
- Storage, inventory and recordkeeping obligations a hydration menu never required.
- Prescription monitoring program checks where your state requires them.
- A different conversation with your insurer and your landlord.
The telehealth question is live and dated
If any part of the program is delivered remotely, the prescribing rules for controlled substances by telehealth are the thing to watch, and they have been moving. This is not a background consideration for a TRT program; it is the thing that determines whether a remote model works at all.
We track it at the DEA telemedicine deadline and the scenarios at what happens January 1, 2027. Build the program so that a change in the rule is a configuration change rather than a business model failure.
The laboratory layer
Hormone programs are built on values, and the temptation to bring testing in-house is immediate. The line is testing rather than blood.
Drawing a specimen and sending it out keeps the certificate with the reference laboratory. Running anything on it in your building makes the building a laboratory, and under 42 CFR § 493.3 it needs a certificate matching what it performs. There is no minimum-volume exception. See CLIA waiver for in-house labs, and the commercial case for draws at in-house lab draws.
Most clinics should start collection-only and decide about in-house testing deliberately later.
What changes clinically, which is also what changes commercially
An IV visit is an episode. A hormone program is a relationship with a monitoring cadence, and the operational differences are real:
| IV hydration | Hormone therapy | |
|---|---|---|
| Encounter | Episodic | Longitudinal, with scheduled review |
| Record | Treatment note | Cumulative chart with trended values |
| Clinician time | At the visit | At the visit and between them |
| Failure mode | A poor experience | A missed finding |
The last row is why this is a different business rather than an additional menu item. A program that does not monitor is not a cheaper program; it is a different and worse one.
Clinical currency matters too: see the hormone therapy boxed warning change for an example of a position that moved.
A sequence that works
- Decide remote, in-person, or both, because the controlled substance rules differ and that decision drives everything after it.
- Register the location or locations before any stock arrives, and start early.
- Start collection-only on labs. Add in-house testing later, with the certificate that matches.
- Build the monitoring cadence into the software rather than into an intention.
- Re-paper the clinical governance. Protocols, delegation and standing orders for a scheduled drug are not the ones you wrote for hydration.
- Tell your insurer what changed. A policy written for a hydration clinic did not contemplate this.
What this means for you
Treat this as opening a second business inside the first, because on the regulatory side that is what it is. Settle the remote-versus-in-person question first, since it determines which rules you are living under and which of them are currently in motion. Register every location before stock arrives rather than after opening, and start collection-only on labs so the CLIA decision is deliberate. Then build the monitoring cadence in from day one, because it is simultaneously the clinical standard, the retention mechanism and the record that makes the program defensible. Our service overview is at hormone therapy.
Related reading
Frequently asked questions
Do I need a DEA registration to offer testosterone therapy?
Yes, where the clinic handles the controlled substance. Registration attaches to the physical location under 21 CFR § 1301.12, so each site needs its own, and many states require a separate state controlled-substance registration as well.
Do I need CLIA to run hormone labs?
Only if testing is performed in your building. Drawing a specimen and sending it to a reference laboratory is not testing. Running anything on it yourself makes the site a laboratory, and 42 CFR § 493.3 requires a certificate matching the complexity performed, with no minimum-volume exception.
Can hormone therapy be delivered by telehealth?
For controlled substances such as testosterone, that depends on prescribing rules that have been moving and carry dates. Design the program so a change in the rule is a configuration change rather than a business model failure, and track the current position before committing to a remote model.
How is a hormone program different from an IV business operationally?
An infusion is an episode; a hormone program is a longitudinal relationship with scheduled monitoring, trended values and clinician time between visits. The failure mode changes from a poor experience to a missed finding, which is why it is a different business rather than an added menu item.
What should I do first?
Decide whether the program is remote, in person or both, because the controlled substance analysis follows from that and everything else follows from the analysis. Then register the locations and start collection-only on labs.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.